Skip to main content
SpringerLink
Log in

Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Five years later, what are the wider impacts of the US Supreme Court's Myriad decision on subject-matter eligibility and patent prosecution for nature-based products beyond isolated DNA?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Study results.

References

  1. Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).

  2. Schor, G.A., Norviel, V. & Cohen, I.G. Brief for amicus curiae Eric S. Lander in support of neither party http://hdl.handle.net/10161/7590 (2013).

    Google Scholar 

  3. Gold, R.E., Cook-Deegan, R. & Bubela, T. Sci. Transl. Med. 5, 192ed9 (2013).

    Article  Google Scholar 

  4. Dilenge, T. et al. Brief for amicus curiae The Biotechnology Industry Organization in support of respondents https://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/briefs-v2/12-398_resp_amcu_bio.authcheckdam.pdf (2013).

    Google Scholar 

  5. Rai, A.K. & Cook-Deegan, R. Science 341, 137–138 (2013).

    Article  CAS  Google Scholar 

  6. Sachs, R. UC Davis Law Rev. 49, 1881–1940 (2015).

    Google Scholar 

  7. Diamond v. Chakrabarty, 100 S. Ct. 2204 (1980).

  8. Funk Brothers Seed Co. v. Kalo Inoculant Co., 68 S. Ct. 440 (1948).

  9. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012).

  10. Alice Corp. v. CLS Bank International, 134 S. Ct. 2347 (2014).

  11. USPTO. 2106 Patent Subject Matter Eligibility [R-08.2017] https://www.uspto.gov/web/offices/pac/mpep/s2106.html

  12. In Re Roslin Institute (Edinburgh), 750 F.3d 1333 (2014).

  13. Rai, A.K. & Sherkow, J.S. Nat. Biotechnol. 34, 292–294 (2016).

    Article  CAS  Google Scholar 

  14. Sherkow, J.S. & Greely, H.T. Annu. Rev. Genet. 49, 161–182 (2015).

    Article  CAS  Google Scholar 

  15. Burk, D.L. Notre Dame Law Rev. 90, 505–542 (2016).

    Google Scholar 

  16. Tallmadge, E.H. Harv. J. Law Technol. 30, 569–600 (2017).

    Google Scholar 

  17. Woessner, W.D. in Patents4Life http://www.patents4life.com/2015/04/isolated-natural-products-still-in-purgatory-post-pto-guidance/ (2015).

    Google Scholar 

  18. Luo, C. & Goldstein, J. in Bloomberg BNA – Life Sciences Law & Industry Report https://www.sternekessler.com/sites/default/files/2017-11/Patenting_Purified_Natural_Products.pdf (2015).

    Google Scholar 

  19. Aboy, M., Liddell, K., Liddicoat, J. & Crespo, C. Nat. Biotechnol. 34, 1119–1123 (2016).

    Article  CAS  Google Scholar 

  20. Aboy, M., Liddicoat, J., Liddell, K., Jordan, M. & Crespo, C. Nat. Biotechnol. 35, 820–825 (2017).

    Article  CAS  Google Scholar 

  21. D'Arcy v. Myriad Genetics, Inc., 325 ALR 100 (2015).

Download references

Author information

Authors and Affiliations

  1. Mateo Aboy, Cristina Crespo, Kathleen Liddell, Johnathon Liddicoat and Matthew Jordan are at the Centre for Law, Medicine, and Life Sciences, Faculty of Law, University of Cambridge, Cambridge, UK.,

    Mateo Aboy, Cristina Crespo, Kathleen Liddell, Johnathon Liddicoat & Matthew Jordan

Authors
  1. Mateo Aboy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Crespo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen Liddell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johnathon Liddicoat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mateo Aboy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text

Supplementary Data and Methods (PDF 633 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aboy, M., Crespo, C., Liddell, K. et al. Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?. Nat Biotechnol 36, 1146–1149 (2018). https://doi.org/10.1038/nbt.4308

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4308

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation